CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
15.23 CAD
+0.12 (+0.79%)
Overall CPH gets a fundamental rating of 7 out of 10. We evaluated CPH against 32 industry peers in the Pharmaceuticals industry. CPH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make CPH suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
In the past year CPH had a positive cash flow from operations.
CPH had positive earnings in each of the past 5 years.
CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CPH has a better Return On Assets (11.77%) than 96.88% of its industry peers.
CPH's Return On Equity of 15.23% is amongst the best of the industry. CPH outperforms 87.50% of its industry peers.
The Return On Invested Capital of CPH (7.23%) is better than 90.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.90%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH has a Profit Margin of 34.68%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
Looking at the Operating Margin, with a value of 25.51%, CPH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
CPH's Operating Margin has declined in the last couple of years.
The Gross Margin of CPH (74.32%) is better than 93.75% of its industry peers.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
The number of shares outstanding for CPH has been increased compared to 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
Compared to 1 year ago, CPH has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.44 indicates that CPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.44, CPH belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
CPH's Debt to FCF ratio of 0.45 is amongst the best of the industry. CPH outperforms 90.63% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
CPH's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CPH outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.44 |
ROIC/WACC0.9
WACC8.05%
2.3 Liquidity
CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 62.50% of the companies in the same industry.
A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
The Quick ratio of CPH (0.98) is comparable to the rest of the industry.
The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.76% over the past year.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
The Revenue has grown by 89.17% in the past year. This is a very strong growth!
Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
The Earnings Per Share is expected to grow by 13.16% on average over the next years. This is quite good.
The Revenue is expected to grow by 21.67% on average over the next years. This is a very strong growth
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.38, CPH is valued correctly.
CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 81.25% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.31. CPH is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 16.55, CPH is valued correctly.
CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 75.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.56, CPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.38 | ||
| Fwd PE | 16.55 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
CPH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CPH is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.22 | ||
| EV/EBITDA | 14.24 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPH may justify a higher PE ratio.
CPH's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.43
PEG (5Y)1.26
EPS Next 2Y19.46%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (11/28/2025, 7:00:00 PM)
15.23
+0.12 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap386.39M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target18.39 (20.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)2.88%
PT rev (3m)2.88%
EPS NQ rev (1m)-6.06%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.15%
Revenue NQ rev (1m)-6.28%
Revenue NQ rev (3m)-6.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.38 | ||
| Fwd PE | 16.55 | ||
| P/S | 5.51 | ||
| P/FCF | 9.22 | ||
| P/OCF | 9.19 | ||
| P/B | 2.42 | ||
| P/tB | 12.07 | ||
| EV/EBITDA | 14.24 |
EPS(TTM)0.93
EY6.11%
EPS(NY)0.92
Fwd EY6.04%
FCF(TTM)1.65
FCFY10.85%
OCF(TTM)1.66
OCFY10.88%
SpS2.77
BVpS6.29
TBVpS1.26
PEG (NY)0.43
PEG (5Y)1.26
Graham Number11.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.44 |
F-Score7
WACC8.05%
ROIC/WACC0.9
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year137.02%
EBIT Next 3Y37.79%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 7 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Undervalued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.